Table 2.
Findings for patients with COVID-19 and liver impairment.
| Non-LBA (n?=?603) |
Liver biochemistry abnormality |
P value |
||||
|---|---|---|---|---|---|---|
| Mild LBA (n?=?195) | LI (n?=?32) |
All LBA (n?=?227) |
P value |
|||
| Age (IQR), y | 49.0 (32.0) | 56.0 (26.0) | 54.5 (31.25) | 56 (27.0) | 0.510 | <0.001 |
| Gender | 0.252 | <0.001 | ||||
| Male | 233 (38.6%) | 121 (62.4%) | 24 (72.7%) | 145 (63.9%) | ||
| Female | 370 (61.4%) | 73 (37.6%) | 9 (27.3%) | 82 (36.1%) | ||
| Laboratory Findings | ||||||
| Triglyceride, mol/L normal range <1.7 |
1.20 (0.87) | 1.20 (0.91) | 1.11 (0.54) | 1.18 (0.88) | 0.213 | 0.506 |
| Cholesterol, mol/L normal range <5.18 |
3.93 (1.33) | 4.01 (1.45) | 3.98 (1.44) | 4.01 (1.34) | 0.458 | 0.657 |
| Lymphocyte count, *10^9/L normal range 1.1-3.2 |
1.19 (0.85) | 1.05 (0.65) | 0.95 (0.51) | 1.01 (0.63) | 0.600 | <0.001 |
| Lymphocyte proportion,% normal range 20-50 |
26.4 (18.68) | 19.60 (16.10) | 15.15 (10.73) | 19.0 (15.45) | 0.193 | <0.001 |
| C-reactive protein, mg/dL normal range 0-0.5 |
0.69 (2.56) | 2.75 (5.27) | 3.14 (5.10) | 2.81 (5.40) | 0.481 | <0.001 |
| d-dimer, µg/mL normal range 0-1 |
0.45 (0.84) | 0.68 (1.30) | 0.62 (1.15) | 0.67 (1.24) | 0.934 | <0.001 |
| Albumin, g/L normal range 40-55 |
40.15 (7.10) | 38.10 (8.35) | 36.80 (6.02) | 37.8 (7.80) | 0.665 | <0.001 |
| ALT, U/L normal range 9-50 |
16.4 (11.67) | 38.1 (31.75) | 135.8 (158.13) | 42.4 (37.35) | <0.001 | <0.001 |
| AST, U/L normal range 15-40 |
18.70 (8.30) | 34.10 (22.15) | 76.85 (110.77) | 36.5 (27.28) | <0.001 | <0.001 |
| AST/ALT ratio | 1.16 (0.62) | 0.89 (0.78) | 0.68 (1.11) | 0.84 (0.85) | 0.175 | <0.001 |
| GGT, U/L normal range 10-60 |
17.05 (14.38) | 55.7 (39.25) | 119.0 (218.73) | 60.9 (64.95) | <0.001 | <0.001 |
| Total bilirubin, µmol/L normal range 2-20.4 |
8.50 (5.40) | 10.70 (9.15) | 15.75 (32.10) | 11.40 (9.85) | 0.007 | <0.001 |
| Elevated troponin I(n), >0.05?ng/mL |
30(5.0%) | 17(8.7%) | 4(12.5%) | 21(9.3%) | 0.522 | 0.066 |
| Comorbidities | ||||||
| Hypertension | 142 (23.5%) | 61 (31.4%) | 9 (27.3%) | 70 (30.8%) | 0.632 | 0.032 |
| Diabetes | 57 (9.5%) | 16 (8.2%) | 3 (9.1%) | 19 (8.4%) | 0.744* | 0.630 |
| Hyperlipidemia | 27 (4.5%) | 7 (3.6%) | 3 (9.1%) | 10 (4.4%) | 0.164* | 0.964 |
| Cardiac or Cardiac-vascular disease | 62 (10.3%) | 21 (10.8%) | 5 (15.2%) | 26 (11.5%) | 0.471 | 0.625 |
| Malignancy | 10 (1.7%) | 2 (1.0%) | 1 (3.0%) | 3 (1.3%) | 0.377* | 0.728 |
| Chronic renal disease | 24 (4.0%) | 2 (1.0%) | 1 (3.0%) | 3 (1.3%) | 0.377* | 0.054 |
| Cerebrovascular disease | 41 (6.8%) | 9 (4.6%) | 6 (18.2%) | 15 (6.6%) | 0.004 | 0.922 |
| Chronic pulmonary disease | 46 (7.6%) | 12 (6.2%) | 5 (15.2%) | 17 (7.5%) | 0.07 | 0.946 |
| Surgery | 47 (7.8%) | 12 (6.2%) | 3 (9.1%) | 15 (6.6%) | 0.463* | 0.562 |
| Liver fibrosis/cirrhosis | 13 (2.2%) | 9 (4.6%) | 2 (6.1%) | 11 (4.8%) | 0.664* | 0.039 |
| HBV | 12 (2.0%) | 5 (2.6%) | 1 (3.0%) | 6 (2.6%) | 0.615* | 0.565 |
| Staging | 0.978 | <0.001 | ||||
| Mild | 5 (0.8%) | 1 (0.5%) | NA | 1 (0.4%) | ||
| Standard | 495 (82.1%) | 132 (68.0%) | 23 (69.7%) | 155 (68.3%) | ||
| Severe | 56 (9.3%) | 36 (18.6%) | 6 (18.2%) | 42 (18.5%) | ||
| Critical | 46 (7.6%) | 25 (12.9%) | 4 (12.1%) | 29 (12.8%) | ||
| Hepatic stenosis on CT | 50 (8.3%) | 37 (19.1%) | 7 (21.2%) | 44 (19.4%) | 0.744 | <0.001 |
| Death | 60 (10.0%) | 33 (17.0%) | 5 (15.2%) | 38 (16.7%) | 0.791 | 0.007 |
Continuous data are expressed as median (IQR) and categorical data as number (%).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, Gamma Glutamyltransferase; HBV, hepatitis B virus; CT, computerized tomography; LBA, liver biochemistry abnormality; LI, liver impairment.